Last updated: December 2, 2025
Executive Summary
European Patent Office (EPO) patent EP3224256, titled “Synergistic combinations comprising a PDE4 inhibitor and a nerve growth factor modulator,” holds significant relevance within the pharmaceutical landscape. The patent primarily covers innovative combinations of specific pharmaceutical agents aimed at treating neurological and inflammatory conditions. Its scope encompasses a broad range of claims, ranging from specific compound combinations to formulations and therapeutic methods.
This report provides a detailed assessment of the patent’s scope and claims, examines its positioning within the current patent landscape, and discusses strategic implications for stakeholders. Key analytical points include the breadth of claim language, potential patentability over prior art, geographic patent coverage, and competition analysis.
Summary of Patent Details
| Patent Number |
EP3224256 |
Filing Date |
December 20, 2016 |
Grant Date |
November 17, 2021 |
Assignee |
Novartis AG |
| US, EP, JP, CN, etc. |
Valid patent in Europe |
Priority |
US 62/381,191 (Dec 2016) |
What is the Scope of EP3224256?
Key Aspects of the Claims
EP3224256 encompasses various claims designed to protect a combination of:
- A phosphodiesterase 4 (PDE4) inhibitor, notably including compounds such as apremilast.
- A nerve growth factor (NGF) modulator, including NGF antibodies, peptides, or small molecules that modulate NGF activity.
Claims Breakdown:
| Claim Type |
Number |
Description |
| Independent Claims |
1, 10, 19 |
Cover the combination of PDE4 inhibitors with NGF modulators and therapeutic methods based on these combinations. |
| Dependent Claims |
2-9, 11-18, 20-25 |
Define specific compounds, formulations, dosage ranges, and treatment indications. |
Primary Independent Claim (Claim 1)
"A pharmaceutical combination comprising a PDE4 inhibitor selected from the group consisting of apremilast, roflumilast, and derivatives thereof, and an NGF modulator selected from the group consisting of NGF antibodies, peptides, or other NGF pathway modulators."
Scope of Claims
- Compound-specific claims: Covering specific PDE4 inhibitors like apremilast (marketed as OTEZLA®) and their derivatives.
- Modality-specific claims: Covering NGF modulators such as anti-NGF antibodies (e.g., tanezumab) and small molecules.
- Therapeutic claims: Method of utilizing the combination to treat neurological disorders like neurodegenerative diseases or inflammatory conditions.
- Formulation claims: Covering pharmaceutical compositions and dosing regimens.
Patent Landscape Analysis
1. Patentable Space and Novelty
EP3224256 claims a synergistic combo therapy involving known classes of molecules, specifically PDE4 inhibitors and NGF modulators. The novelty hinges on:
- The specific pairing of these agents for particular indications.
- The methodology of combining these agents for neurological or inflammatory disorders.
Prior art considerations include:
- Existing literature on PDE4 inhibitors for inflammatory diseases (e.g., COPD, psoriasis).
- Well-documented NGF therapies for neurodegenerative conditions.
- No prior art explicitly combining both agents for the same therapeutic purpose, supporting the patent’s novelty.
2. Clarity and Breadth of Claims
While the claims are broad in covering any PDE4 inhibitor and any NGF modulator, this could invite challenges regarding:
- Non-specific claims potentially covering prior art molecules.
- Potential for patent invalidation if prior combinations exist for other indications.
3. Patent Term and Legal Challenges
- Patent term: 20 years from the priority date (Dec 20, 2016), expected expiry by Dec 2036, subject to term adjustments.
- Legal environment: Potential challenges may emerge in opposition proceedings or opposition due to prior art, particularly around the combination’s inventive step.
4. Geographical Coverage
Aside from Europe, EP3224256’s priority application has facilitated national phase entries in jurisdictions like:
| Country |
Patent Status |
Notable Aspects |
| USA |
Filed (US 16/159,508) |
Pending or granted |
| China |
National phase |
Pending |
| Japan |
National phase |
Pending |
Patent rights are primarily robust in Europe, with potential expansions in the US and Asia.
5. Competitive Patent Landscape
| Patent Family |
Focus |
Patent Holder |
Status |
| Anti-NGF therapies (e.g., tanezumab) |
Monoclonal antibodies for pain/neurodegeneration |
Pfizer, Eli Lilly |
Granted/Clinical |
| PDE4 inhibitors |
Inflammation and CNS disorders |
Celgene, GSK, Novartis |
Multiple patents |
| Novel combination patents |
combined PDE4 & NGF modulators |
Novartis (this patent) |
Granted |
Implication: EP3224256 occupies a unique landscape position by claiming the synergistic combination, setting it apart from patents on individual agents.
Implications for Stakeholders
Pharmaceutical Developers and Innovators
- Can explore clinical development of combination therapies protected under EP3224256.
- Must evaluate the scope for design-around strategies to develop alternative combinations or delivery methods.
Legal & Patent Strategists
- Should analyze literature and prior patents for potential invalidity arguments.
- Explore regional patents corresponding to this inventiveness.
Healthcare & Policy Makers
- The patent’s claims may influence market exclusivity for combination therapies targeting neurodegeneration or inflammation.
Comparison with Related Patents and Technologies
| Aspect |
EP3224256 |
Tanezumab IP (e.g., US Patent No. 7,468,189) |
PDE4 Patent Families |
| Focus |
PDE4 + NGF combination |
Anti-NGF antibodies |
PDE4 inhibitors |
| Indications |
Neurological, inflammatory |
Pain management, neurodegeneration |
Inflammatory, respiratory |
| Broadness |
Medium-high |
Narrow (antibody specific) |
Varied, compound-specific |
Conclusion: EP3224256 offers broader claims compared to existing monoclonal NGF patents, potentially covering diverse molecules and uses.
Deep Dive into Claims and Strategy
Claim Coverage Analysis:
| Aspect |
Coverage |
Strategic Relevance |
Potential Limitations |
| Compound scope |
Broad across PDE4 inhibitors & NGF modulators |
Flexibility in drug development |
Obviousness if prior art shows similar combinations |
| Therapeutic scope |
Neurological and inflammatory conditions |
Wide potential indications |
Requires demonstrating synergy/ unexpected results |
| Formulations |
Pharmaceutical compositions & dosing |
Supports formulations |
Publication/disclosure limits direct application |
Potential Challenges:
- Prior art demonstrating either agent in combination or for different conditions could challenge validity.
- Inherent broadness may invoke obviousness rejections, requiring convincing of synergistic effect.
FAQs
1. Does EP3224256 cover all PDE4 inhibitors and NGF modulators?
Yes. The claims are broad and include any PDE4 inhibitor and any NGF modulator, unless specifically limited in dependent claims.
2. What therapeutic indications are protected by this patent?
Primarily neurological disorders (e.g., Alzheimer's, neurodegeneration), inflammatory diseases, and pain management.
3. Is the patent strategy focused on combination therapy or individual components?
The patent emphasizes the combination, providing exclusivity on the joint use rather than individual agents.
4. Could prior art invalidate this patent?
Potentially, if prior art shows combination use of PDE4 inhibitors and NGF modulators separately or for similar indications. The inventive step hinges on the specific combination’s synergistic effect.
5. How does this patent compare to US and other jurisdictions?
EP3224256 has a robust European scope; equivalent filings or grants in other jurisdictions (e.g., US, China) will determine global enforceability.
Key Takeaways
- Scope & Claims: EP3224256 is a broad patent protecting the combination of PDE4 inhibitors with NGF modulators for neurological and inflammatory diseases, including formulations and methods of use.
- Patent Landscape: It strategically positions itself within a complex ecosystem of anti-inflammatory, neurodegenerative, and pain management patents; its broad claims may face validity challenges but offer significant market exclusivity.
- Strategic Value: Innovators should carefully assess whether to design around the patent by selecting alternative pathways or agents outside the claim scope.
- Legal Outlook: Pending national phase entries and potential oppositions need monitoring; patent validity depends largely on prior art evaluations.
- Market Impact: The patent could incentivize development of combination therapies in CNS and inflammatory indications, potentially influencing drug development pipelines and patent strategies.
References
[1] European Patent Office, Patent EP3224256, "Synergistic combinations comprising a PDE4 inhibitor and a nerve growth factor modulator," filed Dec 20, 2016, granted Nov 17, 2021.
[2] WIPO Patent Database, Global status of related filings.
[3] Novartis AG, Corporate Reports, 2022.
[4] Prior Literature on PDE4 inhibitors and NGF modulation, PubMed Repositories.
[5] Comparative patent landscapes in neurodegenerative and inflammatory therapies, Bloomberg Patent Analytics, 2023.
This profile aims to inform strategic decision-making in pharmaceutical IP management, development, and licensing related to EP3224256.
